#229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB

Episode Summary

Executive Summary: This episode compiles prior discussions on ASCVD, cholesterol, and ApoB to argue that atherosclerosis is common, begins decades before symptoms, and is best prevented by early, aggressive reduction of ApoB-bearing lipoproteins. The hosts reject “good/bad cholesterol” language, explain why LDL-C is an imperfect proxy, and emphasize ApoB as the most useful marker of atherogenic particle burden.

Main Topics: Why ASCVD matters for longevity (Priority: 5/5): Atherosclerosis is presented as ubiquitous, largely inevitable with aging, and a major threat to lifespan; prevention matters because disease begins long before clinical events. Natural history and early onset of disease (Priority: 5/5): The discussion stresses that coronary disease develops silently over decades, with many first events occurring before age 65 and even before 55 in men. What cholesterol is and why it is essential (Priority: 4/5): Cholesterol is described as vital for cell membranes, steroid hormones, and bile acids, making it biologically indispensable despite its role in disease. Lipoproteins, ApoB, and transport biology (Priority: 5/5): Because cholesterol is hydrophobic, the body packages it in lipoproteins; ApoB-bearing particles (LDL, VLDL, IDL, Lp(a)) are the atherogenic ones. Why ‘good’ and ‘bad’ cholesterol is misleading (Priority: 4/5): The speakers argue that HDL and LDL are lipoproteins, not cholesterol types, and that HDL-C and LDL-C are laboratory measures that should not be morally labeled. Limitations of LDL-C and triglycerides (Priority: 5/5): LDL-C is often calculated rather than directly measured, triglycerides are an incomplete surrogate, and both can miss particle burden and discordance in metabolic disease. ApoB as the preferred risk metric and treatment target (Priority: 5/5): ApoB is framed as the best single marker of atherogenic particle number and a stronger causal/risk signal than LDL-C or non-HDL-C, supporting earlier and lower treatment targets.

Key Arguments: ASCVD is the most important chronic disease to understand because it is common, often silent for decades, and strongly affects longevity. Atherosclerosis begins in youth; by the time risk calculators recommend treatment, arterial disease may already be advanced. The first presentation of coronary disease can be sudden death, making prevention more important than waiting for symptoms. Cholesterol itself is essential to life; the problem is not cholesterol in general but ApoB-containing particles entering and damaging artery walls. LDL and HDL are lipoproteins, while LDL-C and HDL-C are cholesterol measurements; calling them “good” or “bad” cholesterol is scientifically imprecise. LDL-C is frequently calculated, not directly measured, and does not capture the number of atherogenic particles as well as ApoB does. Triglycerides are associated with risk, but the causal issue is usually the number of ApoB-containing particles, not triglyceride mass itself. Mendelian randomization and pharmacologic trials support ApoB as causal for ASCVD, whereas HDL-C has not shown causal benefit when manipulated. Lower ApoB earlier is better; waiting for a positive calcium score or older age misses the window when prevention is most effective. Very low ApoB levels seen in children and achieved pharmacologically in adults do not appear harmful in current evidence.

Data Points: First heart attack fatality rate: Over 50% historically; now slightly below 50% - Used to emphasize that the first coronary event is often death rather than a survivable warning sign. Men with first cardiac event before age 65: Slightly above 50% - From the age-distribution discussion of major adverse cardiac events in the U.S. Women with first cardiac event before age 65: About one third - Shows women experience ASCVD later on average, but still commonly before older age. Men with first event before age 54: Almost 25% - Highlighted as especially sobering because disease is already active decades earlier. Women’s event timing: About a decade later than men - Describes the sex difference in age distribution of first major cardiac events. 10-year risk calculator limitation: Prevention often begins around age 55–60 - Risk-based guidelines tend to delay treatment until later life, missing earlier disease development. ApoB at age 35 if high: ~95% chance of staying high - Used to argue that ApoB is a stable early-life signal and useful for early intervention. ApoB at age 35 if high (alternate phrasing): About 90% likely to remain high - Reinforces persistence of elevated ApoB over time. 20th percentile of ApoB: About 80 mg/dL - Referenced as a benchmark in discussing treatment thresholds and population distribution. Infant/child ApoB levels: 30–40 mg/dL - Presented as physiologic levels suggesting very low ApoB is normal and not harmful. Potential ApoB ceiling proposed: 60 mg/dL - Suggested as a practical upper limit for many adults in aggressive prevention. Potential ApoB target range: 20–30 mg/dL - Presented as a thought experiment for eliminating ASCVD if achieved early in life. Current pharmacologic ApoB levels achievable: 20–40 mg/dL - Noted with PCSK9 inhibitors and modern lipid-lowering therapy. Total cholesterol example: 200 mg/dL to 100 mg/dL - Used to explain that halving plasma cholesterol does not mean halving total body cholesterol. LDL-C example: 150 mg/dL to 75 mg/dL - Illustrates that lowering circulating LDL-C substantially does not deplete cellular cholesterol stores. LDL-C treatment threshold concept: 50% reduction - Guidelines often seek at least a 50% reduction in higher-risk patients. Coronary calcium example patient: Late 60s, LDL-C 220 mg/dL, ApoB 170 mg/dL, CAC score 0 - Used as an exception illustrating that risk assessment must be individualized. Total cholesterol example patient: 300+ mg/dL - Part of the same exception case showing very high lipids can coexist with zero CAC.

Pivotal Quotes: "Atherosclerosis is really the only inevitable disease of our species." — Peter Atiyah: Explaining why ASCVD deserves attention even in younger listeners. "No cholesterol, no life, period." — Peter Atiyah: Clarifying that cholesterol is essential biology, not inherently harmful. "There is no such thing as good cholesterol or bad cholesterol." — Peter Atiyah: Rejecting simplistic labeling of HDL and LDL and emphasizing correct terminology.

Implications: Listeners should think about ASCVD as a decades-long process and prioritize early ApoB measurement and reduction. For clinicians, the episode argues for moving beyond LDL-C alone toward particle-based prevention and earlier intervention.